Driving T-cell immunotherapy to solid tumors
Author:
- 6 March 2018
- journal article
- editorial
- Published by Springer Nature in Nature Biotechnology
- Vol. 36 (3) , 215-219
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor RegressionsClinical Cancer Research, 2014
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaBlood, 2013
- Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selectionBlood, 2013
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene TherapyJournal of Immunotherapy, 2013
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1Journal of Clinical Oncology, 2011
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- In vitroevolution of a T cell receptor with high affinity for peptide/MHCProceedings of the National Academy of Sciences, 2000
- Transfer of specificity by murine α and β T-cell receptor genesNature, 1986